CA2919382A1 - Therapeutically active compounds and their methods of use - Google Patents

Info

Publication number

CA2919382A1

CA2919382A1 CA2919382A CA2919382A CA2919382A1 CA 2919382 A1 CA2919382 A1 CA 2919382A1 CA 2919382 A CA2919382 A CA 2919382A CA 2919382 A CA2919382 A CA 2919382A CA 2919382 A1 CA2919382 A1 CA 2919382A1

Authority

CA

Canada

Prior art keywords

compound

crystalline form

dose

idh2

ray powder

Prior art date

2013-08-02

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Abandoned

Links

• Espacenet
• Global Dossier
• CIPO
• Discuss

• 238000000034 method Methods 0.000 title claims abstract description 181
• 150000001875 compounds Chemical class 0.000 title abstract description 43
• 238000000634 powder X-ray diffraction Methods 0.000 claims abstract description 43
• 229940125904 compound 1 Drugs 0.000 claims description 376
• 229940126214 compound 3 Drugs 0.000 claims description 238
• 239000012458 free base Substances 0.000 claims description 143
• 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 140
• 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 139
• 201000003793 Myelodysplastic syndrome Diseases 0.000 claims description 127
• 108700028369 Alleles Proteins 0.000 claims description 82
• 208000002250 Hematologic Neoplasms Diseases 0.000 claims description 71
• 201000010902 chronic myelomonocytic leukemia Diseases 0.000 claims description 64
• 206010025323 Lymphomas Diseases 0.000 claims description 54
• 206010008583 Chloroma Diseases 0.000 claims description 51
• 201000005987 myeloid sarcoma Diseases 0.000 claims description 51
• 208000034578 Multiple myelomas Diseases 0.000 claims description 50
• 206010035226 Plasma cell myeloma Diseases 0.000 claims description 50
• 206010042971 T-cell lymphoma Diseases 0.000 claims description 47
• 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 claims description 47
• 239000008194 pharmaceutical composition Substances 0.000 claims description 42
• 201000005787 hematologic cancer Diseases 0.000 claims description 34
• 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims description 34
• 239000003937 drug carrier Substances 0.000 claims description 26
• 239000006186 oral dosage form Substances 0.000 claims description 23
• 101000599886 Homo sapiens Isocitrate dehydrogenase [NADP], mitochondrial Proteins 0.000 claims description 21
• 150000003839 salts Chemical class 0.000 claims description 18
• AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 claims description 14
• 102100037845 Isocitrate dehydrogenase [NADP], mitochondrial Human genes 0.000 claims description 10
• 239000000203 mixture Substances 0.000 abstract description 54
• 239000003112 inhibitor Substances 0.000 abstract description 35
• 206010028980 Neoplasm Diseases 0.000 abstract description 33
• 201000011510 cancer Diseases 0.000 abstract description 14
• 238000009472 formulation Methods 0.000 abstract description 11
• 102000012011 Isocitrate Dehydrogenase Human genes 0.000 abstract description 7
• 108010075869 Isocitrate Dehydrogenase Proteins 0.000 abstract description 7
• 238000001727 in vivo Methods 0.000 abstract description 3
• 238000004090 dissolution Methods 0.000 abstract description 2
• 238000011282 treatment Methods 0.000 description 136
• 238000002411 thermogravimetry Methods 0.000 description 72
• 238000000113 differential scanning calorimetry Methods 0.000 description 69
• 239000000523 sample Substances 0.000 description 64
• XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Natural products CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 56
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 52
• CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 48
• 239000003826 tablet Substances 0.000 description 48
• 230000035772 mutation Effects 0.000 description 46
• 201000010099 disease Diseases 0.000 description 44
• 210000001185 bone marrow Anatomy 0.000 description 37
• 229940079593 drug Drugs 0.000 description 37
• 239000003814 drug Substances 0.000 description 37
• 102200116484 rs121913502 Human genes 0.000 description 37
• 230000004044 response Effects 0.000 description 36
• 238000006243 chemical reaction Methods 0.000 description 35
• 230000008859 change Effects 0.000 description 34
• 239000000243 solution Substances 0.000 description 34
• 230000006870 function Effects 0.000 description 32
• 210000004369 blood Anatomy 0.000 description 31
• 239000008280 blood Substances 0.000 description 31
• 210000004027 cell Anatomy 0.000 description 30
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 29
• 230000006698 induction Effects 0.000 description 28
• 230000007704 transition Effects 0.000 description 28
• 208000003950 B-cell lymphoma Diseases 0.000 description 27
• 239000000155 melt Substances 0.000 description 27
• 230000000694 effects Effects 0.000 description 26
• VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 26
• 238000002203 pretreatment Methods 0.000 description 26
• 239000007787 solid Substances 0.000 description 26
• 210000002700 urine Anatomy 0.000 description 26
• AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 25
• 230000003285 pharmacodynamic effect Effects 0.000 description 24
• 238000004458 analytical method Methods 0.000 description 23
• 230000005764 inhibitory process Effects 0.000 description 23
• 239000011541 reaction mixture Substances 0.000 description 23
• IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 22
• 239000000843 powder Substances 0.000 description 22
• 238000011156 evaluation Methods 0.000 description 21
• 238000002360 preparation method Methods 0.000 description 20
• 238000002560 therapeutic procedure Methods 0.000 description 20
• 229910016523 CuKa Inorganic materials 0.000 description 19
• 239000011886 peripheral blood Substances 0.000 description 19
• 230000005855 radiation Effects 0.000 description 19
• 238000005070 sampling Methods 0.000 description 19
• UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 17
• 230000015572 biosynthetic process Effects 0.000 description 17
• 210000005259 peripheral blood Anatomy 0.000 description 17
• 208000016261 weight loss Diseases 0.000 description 17
• 230000004580 weight loss Effects 0.000 description 17
• 239000002904 solvent Substances 0.000 description 16
• 101000599885 Dictyostelium discoideum Isocitrate dehydrogenase [NADP], mitochondrial Proteins 0.000 description 15
• 102100022678 Nucleophosmin Human genes 0.000 description 15
• 210000003969 blast cell Anatomy 0.000 description 15
• 230000034994 death Effects 0.000 description 15
• 231100000517 death Toxicity 0.000 description 15
• 208000020442 loss of weight Diseases 0.000 description 15
• 235000002639 sodium chloride Nutrition 0.000 description 15
• 238000001757 thermogravimetry curve Methods 0.000 description 15
• YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 14
• 208000032839 leukemia Diseases 0.000 description 14
• 230000009467 reduction Effects 0.000 description 14
• 239000000725 suspension Substances 0.000 description 14
• 238000003786 synthesis reaction Methods 0.000 description 14
• 208000033833 Myelomonocytic Chronic Leukemia Diseases 0.000 description 13
• 231100000371 dose-limiting toxicity Toxicity 0.000 description 13
• 231100000682 maximum tolerated dose Toxicity 0.000 description 13
• 238000012216 screening Methods 0.000 description 13
• 101001109719 Homo sapiens Nucleophosmin Proteins 0.000 description 12
• 238000007596 consolidation process Methods 0.000 description 12
• HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 12
• 238000004519 manufacturing process Methods 0.000 description 12
• 239000012299 nitrogen atmosphere Substances 0.000 description 12
• WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Substances C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 12
• IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 11
• 102000004190 Enzymes Human genes 0.000 description 11
• 108090000790 Enzymes Proteins 0.000 description 11
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical class CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 11
• 102100020718 Receptor-type tyrosine-protein kinase FLT3 Human genes 0.000 description 11
• 101710151245 Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 description 11
• 230000002411 adverse Effects 0.000 description 11
• 230000001419 dependent effect Effects 0.000 description 11
• 210000000440 neutrophil Anatomy 0.000 description 11
• 210000002381 plasma Anatomy 0.000 description 11
• 230000002829 reductive effect Effects 0.000 description 11
• 239000002002 slurry Substances 0.000 description 11
• UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 10
• 238000001574 biopsy Methods 0.000 description 10
• 229940125782 compound 2 Drugs 0.000 description 10
• DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 10
• 230000007423 decrease Effects 0.000 description 10
• 230000003247 decreasing effect Effects 0.000 description 10
• 230000004069 differentiation Effects 0.000 description 10
• 230000002401 inhibitory effect Effects 0.000 description 10
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 10
• 238000003756 stirring Methods 0.000 description 10
• 239000000126 substance Substances 0.000 description 10
• 102100024812 DNA (cytosine-5)-methyltransferase 3A Human genes 0.000 description 9
• 108010033040 Histones Proteins 0.000 description 9
• 239000003795 chemical substances by application Substances 0.000 description 9
• 238000002512 chemotherapy Methods 0.000 description 9
• 230000000155 isotopic effect Effects 0.000 description 9
• OCKGFTQIICXDQW-ZEQRLZLVSA-N 5-[(1r)-1-hydroxy-2-[4-[(2r)-2-hydroxy-2-(4-methyl-1-oxo-3h-2-benzofuran-5-yl)ethyl]piperazin-1-yl]ethyl]-4-methyl-3h-2-benzofuran-1-one Chemical compound C1=C2C(=O)OCC2=C(C)C([C@@H](O)CN2CCN(CC2)C[C@H](O)C2=CC=C3C(=O)OCC3=C2C)=C1 OCKGFTQIICXDQW-ZEQRLZLVSA-N 0.000 description 8
• 102100034808 CCAAT/enhancer-binding protein alpha Human genes 0.000 description 8
• RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Natural products CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
• 206010061818 Disease progression Diseases 0.000 description 8
• KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 8
• 230000002559 cytogenic effect Effects 0.000 description 8
• 230000005750 disease progression Effects 0.000 description 8
• 208000035475 disorder Diseases 0.000 description 8
• 239000010410 layer Substances 0.000 description 8
• 238000010992 reflux Methods 0.000 description 8
• 235000017557 sodium bicarbonate Nutrition 0.000 description 8
• 229910000030 sodium bicarbonate Inorganic materials 0.000 description 8
• 239000012453 solvate Substances 0.000 description 8
• 210000000130 stem cell Anatomy 0.000 description 8
• BWGRDBSNKQABCB-UHFFFAOYSA-N 4,4-difluoro-N-[3-[3-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octan-8-yl]-1-thiophen-2-ylpropyl]cyclohexane-1-carboxamide Chemical compound CC(C)C1=NN=C(C)N1C1CC2CCC(C1)N2CCC(NC(=O)C1CCC(F)(F)CC1)C1=CC=CS1 BWGRDBSNKQABCB-UHFFFAOYSA-N 0.000 description 7
• 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 7
• 101710168309 CCAAT/enhancer-binding protein alpha Proteins 0.000 description 7
• 238000004820 blood count Methods 0.000 description 7
• 239000013078 crystal Substances 0.000 description 7
• 229960000684 cytarabine Drugs 0.000 description 7
• 238000002565 electrocardiography Methods 0.000 description 7
• 239000000463 material Substances 0.000 description 7
• 239000002207 metabolite Substances 0.000 description 7
• 229940098779 methanesulfonic acid Drugs 0.000 description 7
• 230000036961 partial effect Effects 0.000 description 7
• 108090000623 proteins and genes Proteins 0.000 description 7
• 210000002966 serum Anatomy 0.000 description 7
• 208000024891 symptom Diseases 0.000 description 7
• OKBHXGBLXDNJJD-UHFFFAOYSA-N 6-(trifluoromethyl)pyridine-2-carboxylic acid Chemical compound OC(=O)C1=CC=CC(C(F)(F)F)=N1 OKBHXGBLXDNJJD-UHFFFAOYSA-N 0.000 description 6
• WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 6
• 108010024491 DNA Methyltransferase 3A Proteins 0.000 description 6
• 101000728236 Homo sapiens Polycomb group protein ASXL1 Proteins 0.000 description 6
• 102100029799 Polycomb group protein ASXL1 Human genes 0.000 description 6
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
• XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 6
• 210000002798 bone marrow cell Anatomy 0.000 description 6
• 239000012267 brine Substances 0.000 description 6
• 238000012512 characterization method Methods 0.000 description 6
• 239000003085 diluting agent Substances 0.000 description 6
• 239000002552 dosage form Substances 0.000 description 6
• 210000003743 erythrocyte Anatomy 0.000 description 6
• 238000010438 heat treatment Methods 0.000 description 6
• 230000006872 improvement Effects 0.000 description 6
• 239000007788 liquid Substances 0.000 description 6
• 235000019359 magnesium stearate Nutrition 0.000 description 6
• 238000005259 measurement Methods 0.000 description 6
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 6
• 230000002085 persistent effect Effects 0.000 description 6
• 230000000704 physical effect Effects 0.000 description 6
• 108090000765 processed proteins & peptides Proteins 0.000 description 6
• 235000018102 proteins Nutrition 0.000 description 6
• 102000004169 proteins and genes Human genes 0.000 description 6
• HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 6
• 239000000758 substrate Substances 0.000 description 6
• 230000004083 survival effect Effects 0.000 description 6
• 231100000419 toxicity Toxicity 0.000 description 6
• 230000001988 toxicity Effects 0.000 description 6
• 210000004881 tumor cell Anatomy 0.000 description 6
• 239000003981 vehicle Substances 0.000 description 6
• 102000001554 Hemoglobins Human genes 0.000 description 5
• 108010054147 Hemoglobins Proteins 0.000 description 5
• 101000823298 Homo sapiens Broad substrate specificity ATP-binding cassette transporter ABCG2 Proteins 0.000 description 5
• BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 5
• 229920000168 Microcrystalline cellulose Polymers 0.000 description 5
• 241000699670 Mus sp. Species 0.000 description 5
• 201000007224 Myeloproliferative neoplasm Diseases 0.000 description 5
• 238000005481 NMR spectroscopy Methods 0.000 description 5
• KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 5
• HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 5
• 239000004480 active ingredient Substances 0.000 description 5
• 239000002671 adjuvant Substances 0.000 description 5
• 150000001413 amino acids Chemical class 0.000 description 5
• 230000008901 benefit Effects 0.000 description 5
• 229940075614 colloidal silicon dioxide Drugs 0.000 description 5
• 229940109239 creatinine Drugs 0.000 description 5
• 238000002425 crystallisation Methods 0.000 description 5
• 230000008025 crystallization Effects 0.000 description 5
• 239000007789 gas Substances 0.000 description 5
• 230000014509 gene expression Effects 0.000 description 5
• 230000002489 hematologic effect Effects 0.000 description 5
• 230000003834 intracellular effect Effects 0.000 description 5
• 238000002483 medication Methods 0.000 description 5
• 229940016286 microcrystalline cellulose Drugs 0.000 description 5
• 235000019813 microcrystalline cellulose Nutrition 0.000 description 5
• 239000008108 microcrystalline cellulose Substances 0.000 description 5
• 238000012986 modification Methods 0.000 description 5
• 210000000056 organ Anatomy 0.000 description 5
• 229920001184 polypeptide Polymers 0.000 description 5
• 102000004196 processed proteins & peptides Human genes 0.000 description 5
• 229940079832 sodium starch glycolate Drugs 0.000 description 5
• 239000008109 sodium starch glycolate Substances 0.000 description 5
• 229920003109 sodium starch glycolate Polymers 0.000 description 5
• 102100033350 ATP-dependent translocase ABCB1 Human genes 0.000 description 4
• 102100022595 Broad substrate specificity ATP-binding cassette transporter ABCG2 Human genes 0.000 description 4
• 206010064571 Gene mutation Diseases 0.000 description 4
• 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 4
• 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 4
• MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 4
• BAWFJGJZGIEFAR-NNYOXOHSSA-M NAD(1-) Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP([O-])(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-M 0.000 description 4
• XJLXINKUBYWONI-NNYOXOHSSA-O NADP(+) Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-NNYOXOHSSA-O 0.000 description 4
• PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 4
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
• 230000005856 abnormality Effects 0.000 description 4
• 210000001124 body fluid Anatomy 0.000 description 4
• 238000011161 development Methods 0.000 description 4
• 230000018109 developmental process Effects 0.000 description 4
• 238000003745 diagnosis Methods 0.000 description 4
• 239000002270 dispersing agent Substances 0.000 description 4
• -1 e.g. Inorganic materials 0.000 description 4
• 235000019441 ethanol Nutrition 0.000 description 4
• ODBLHEXUDAPZAU-UHFFFAOYSA-N isocitric acid Chemical compound OC(=O)C(O)C(C(O)=O)CC(O)=O ODBLHEXUDAPZAU-UHFFFAOYSA-N 0.000 description 4
• JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropanol acetate Natural products CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 description 4
• 210000000265 leukocyte Anatomy 0.000 description 4
• AYABEJGGSWJVPN-UHFFFAOYSA-N methyl 6-(trifluoromethyl)pyridine-2-carboxylate Chemical compound COC(=O)C1=CC=CC(C(F)(F)F)=N1 AYABEJGGSWJVPN-UHFFFAOYSA-N 0.000 description 4
• 208000004235 neutropenia Diseases 0.000 description 4
• 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 4
• 239000012044 organic layer Substances 0.000 description 4
• 230000036470 plasma concentration Effects 0.000 description 4
• 230000008569 process Effects 0.000 description 4
• 238000010926 purge Methods 0.000 description 4
• 102220043690 rs1049562 Human genes 0.000 description 4
• 238000003860 storage Methods 0.000 description 4
• 230000002485 urinary effect Effects 0.000 description 4
• CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 3
• 240000000560 Citrus x paradisi Species 0.000 description 3
• PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 description 3
• 229920000858 Cyclodextrin Polymers 0.000 description 3
• 108010074922 Cytochrome P-450 CYP1A2 Proteins 0.000 description 3
• 102100026533 Cytochrome P450 1A2 Human genes 0.000 description 3
• 101000785401 Drosophila melanogaster Polycomb protein Asx Proteins 0.000 description 3
• 101000909242 Homo sapiens DNA (cytosine-5)-methyltransferase 3A Proteins 0.000 description 3
• 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 3
• 101710175291 Isocitrate dehydrogenase [NADP], mitochondrial Proteins 0.000 description 3
• 108010025568 Nucleophosmin Proteins 0.000 description 3
• 206010033661 Pancytopenia Diseases 0.000 description 3
• 208000010954 Partial deletion of the long arm of chromosome 7 Diseases 0.000 description 3
• 108010089430 Phosphoproteins Proteins 0.000 description 3
• 102000007982 Phosphoproteins Human genes 0.000 description 3
• DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
• CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 3
• DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
• YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
• 206010053871 Trisomy 8 Diseases 0.000 description 3
• 230000002159 abnormal effect Effects 0.000 description 3
• 230000004075 alteration Effects 0.000 description 3
• 229940024606 amino acid Drugs 0.000 description 3
• 235000001014 amino acid Nutrition 0.000 description 3
• 239000000090 biomarker Substances 0.000 description 3
• 235000011089 carbon dioxide Nutrition 0.000 description 3
• 239000000969 carrier Substances 0.000 description 3
• 230000024245 cell differentiation Effects 0.000 description 3
• 210000001175 cerebrospinal fluid Anatomy 0.000 description 3
• 208000024389 cytopenia Diseases 0.000 description 3
• 230000001934 delay Effects 0.000 description 3
• 238000009792 diffusion process Methods 0.000 description 3
• 238000009826 distribution Methods 0.000 description 3
• 231100000673 dose–response relationship Toxicity 0.000 description 3
• 238000001647 drug administration Methods 0.000 description 3
• 239000003995 emulsifying agent Substances 0.000 description 3
• 239000000839 emulsion Substances 0.000 description 3
• 238000001704 evaporation Methods 0.000 description 3
• 230000008020 evaporation Effects 0.000 description 3
• 210000003714 granulocyte Anatomy 0.000 description 3
• 230000012010 growth Effects 0.000 description 3
• 230000036541 health Effects 0.000 description 3
• 239000001863 hydroxypropyl cellulose Substances 0.000 description 3
• 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 3
• 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 3
• 230000006607 hypermethylation Effects 0.000 description 3
• 230000000977 initiatory effect Effects 0.000 description 3
• 238000002347 injection Methods 0.000 description 3
• 239000007924 injection Substances 0.000 description 3
• 230000036210 malignancy Effects 0.000 description 3
• 235000012054 meals Nutrition 0.000 description 3
• 108020004999 messenger RNA Proteins 0.000 description 3
• 230000004060 metabolic process Effects 0.000 description 3
• 230000011987 methylation Effects 0.000 description 3
• 238000007069 methylation reaction Methods 0.000 description 3
• 238000002156 mixing Methods 0.000 description 3
• 230000004048 modification Effects 0.000 description 3
• 231100000252 nontoxic Toxicity 0.000 description 3
• 230000003000 nontoxic effect Effects 0.000 description 3
• 239000003208 petroleum Substances 0.000 description 3
• 229920001223 polyethylene glycol Polymers 0.000 description 3
• 238000001556 precipitation Methods 0.000 description 3
• 238000011084 recovery Methods 0.000 description 3
• 102220197847 rs121913502 Human genes 0.000 description 3
• 102220197849 rs267606870 Human genes 0.000 description 3
• 235000019333 sodium laurylsulphate Nutrition 0.000 description 3
• 239000011877 solvent mixture Substances 0.000 description 3
• 238000001179 sorption measurement Methods 0.000 description 3
• 210000000278 spinal cord Anatomy 0.000 description 3
• 150000003431 steroids Chemical class 0.000 description 3
• 238000006467 substitution reaction Methods 0.000 description 3
• 208000011580 syndromic disease Diseases 0.000 description 3
• 230000001225 therapeutic effect Effects 0.000 description 3
• 208000034298 trisomy chromosome 8 Diseases 0.000 description 3
• PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
• KFZMGEQAYNKOFK-WFGJKAKNSA-N 1,1,1,3,3,3-hexadeuteriopropan-2-ol Chemical compound [2H]C([2H])([2H])C(O)C([2H])([2H])[2H] KFZMGEQAYNKOFK-WFGJKAKNSA-N 0.000 description 2
• OSIPHTAXRZMCDG-UHFFFAOYSA-N 1,1-bis(methylamino)ethanol Chemical compound CNC(C)(O)NC OSIPHTAXRZMCDG-UHFFFAOYSA-N 0.000 description 2
• GSSCQXYNRDFGAV-UHFFFAOYSA-N 2,4-dichloro-6-[6-(trifluoromethyl)pyridin-2-yl]-1,3,5-triazine Chemical compound FC(F)(F)C1=CC=CC(C=2N=C(Cl)N=C(Cl)N=2)=N1 GSSCQXYNRDFGAV-UHFFFAOYSA-N 0.000 description 2
• LYNBZRJTRHTSKI-UHFFFAOYSA-N 2-(trifluoromethyl)pyridin-4-amine Chemical compound NC1=CC=NC(C(F)(F)F)=C1 LYNBZRJTRHTSKI-UHFFFAOYSA-N 0.000 description 2
• ATRQECRSCHYSNP-UHFFFAOYSA-N 2-(trifluoromethyl)pyridine Chemical compound FC(F)(F)C1=CC=CC=N1 ATRQECRSCHYSNP-UHFFFAOYSA-N 0.000 description 2
• 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 2
• SXFBKPOTJNVNEW-UHFFFAOYSA-N 4-chloro-n-[2-(trifluoromethyl)pyridin-4-yl]-6-[6-(trifluoromethyl)pyridin-2-yl]-1,3,5-triazin-2-amine Chemical compound FC(F)(F)C1=CC=CC(C=2N=C(NC=3C=C(N=CC=3)C(F)(F)F)N=C(Cl)N=2)=N1 SXFBKPOTJNVNEW-UHFFFAOYSA-N 0.000 description 2
• XAUDJQYHKZQPEU-KVQBGUIXSA-N 5-aza-2'-deoxycytidine Chemical compound O=C1N=C(N)N=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 XAUDJQYHKZQPEU-KVQBGUIXSA-N 0.000 description 2
• JBXAKQJKSGOFNP-UHFFFAOYSA-N 6-[6-(trifluoromethyl)pyridin-2-yl]-1h-1,3,5-triazine-2,4-dione Chemical compound FC(F)(F)C1=CC=CC(C=2NC(=O)NC(=O)N=2)=N1 JBXAKQJKSGOFNP-UHFFFAOYSA-N 0.000 description 2
• QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
• WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 2
• 206010067484 Adverse reaction Diseases 0.000 description 2
• 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 2
• 108010082126 Alanine transaminase Proteins 0.000 description 2
• 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
• 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
• 201000004384 Alopecia Diseases 0.000 description 2
• 235000012905 Brassica oleracea var viridis Nutrition 0.000 description 2
• 201000004085 CLL/SLL Diseases 0.000 description 2
• 208000031404 Chromosome Aberrations Diseases 0.000 description 2
• 229920002261 Corn starch Polymers 0.000 description 2
• 108010026925 Cytochrome P-450 CYP2C19 Proteins 0.000 description 2
• 108010001237 Cytochrome P-450 CYP2D6 Proteins 0.000 description 2
• 102100029363 Cytochrome P450 2C19 Human genes 0.000 description 2
• 102000018832 Cytochromes Human genes 0.000 description 2
• 108010052832 Cytochromes Proteins 0.000 description 2
• 108020004414 DNA Proteins 0.000 description 2
• 102000053602 DNA Human genes 0.000 description 2
• YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 2
• 206010012735 Diarrhoea Diseases 0.000 description 2
• ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
• 208000009139 Gilbert Disease Diseases 0.000 description 2
• 208000022412 Gilbert syndrome Diseases 0.000 description 2
• DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
• 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 2
• 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 2
• XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 2
• XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 description 2
• 101150104906 Idh2 gene Proteins 0.000 description 2
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
• 241001465754 Metazoa Species 0.000 description 2
• UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 description 2
• 206010028813 Nausea Diseases 0.000 description 2
• 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 2
• 239000002202 Polyethylene glycol Substances 0.000 description 2
• 206010037660 Pyrexia Diseases 0.000 description 2
• 208000033501 Refractory anemia with excess blasts Diseases 0.000 description 2
• 208000034442 Refractory anemia with excess blasts type 1 Diseases 0.000 description 2
• 208000034432 Refractory anemia with excess blasts type 2 Diseases 0.000 description 2
• 208000004756 Respiratory Insufficiency Diseases 0.000 description 2
• 206010040047 Sepsis Diseases 0.000 description 2
• KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
• QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
• KLBQZWRITKRQQV-UHFFFAOYSA-N Thioridazine Chemical compound C12=CC(SC)=CC=C2SC2=CC=CC=C2N1CCC1CCCCN1C KLBQZWRITKRQQV-UHFFFAOYSA-N 0.000 description 2
• 206010044685 Trisomy 11 Diseases 0.000 description 2
• 102100029152 UDP-glucuronosyltransferase 1A1 Human genes 0.000 description 2
• 101710205316 UDP-glucuronosyltransferase 1A1 Proteins 0.000 description 2
• XCCTYIAWTASOJW-XVFCMESISA-N Uridine-5'-Diphosphate Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(=O)OP(O)(O)=O)O[C@H]1N1C(=O)NC(=O)C=C1 XCCTYIAWTASOJW-XVFCMESISA-N 0.000 description 2
• 102000013127 Vimentin Human genes 0.000 description 2
• 108010065472 Vimentin Proteins 0.000 description 2
• WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 2
• 239000012346 acetyl chloride Substances 0.000 description 2
• 230000001154 acute effect Effects 0.000 description 2
• 230000006838 adverse reaction Effects 0.000 description 2
• 231100000360 alopecia Toxicity 0.000 description 2
• 208000022531 anorexia Diseases 0.000 description 2
• 229940045799 anthracyclines and related substance Drugs 0.000 description 2
• 239000007900 aqueous suspension Substances 0.000 description 2
• 235000019445 benzyl alcohol Nutrition 0.000 description 2
• OHJMTUPIZMNBFR-UHFFFAOYSA-N biuret Chemical compound NC(=O)NC(N)=O OHJMTUPIZMNBFR-UHFFFAOYSA-N 0.000 description 2
• 239000010836 blood and blood product Substances 0.000 description 2
• 210000000601 blood cell Anatomy 0.000 description 2
• 229940125691 blood product Drugs 0.000 description 2
• 230000037396 body weight Effects 0.000 description 2
• 239000000872 buffer Substances 0.000 description 2
• 235000014121 butter Nutrition 0.000 description 2
• 239000002775 capsule Substances 0.000 description 2
• 239000001768 carboxy methyl cellulose Substances 0.000 description 2
• 239000003153 chemical reaction reagent Substances 0.000 description 2
• 208000023738 chronic lymphocytic leukemia/small lymphocytic lymphoma Diseases 0.000 description 2
• 235000020971 citrus fruits Nutrition 0.000 description 2
• 229960002436 cladribine Drugs 0.000 description 2
• WDDPHFBMKLOVOX-AYQXTPAHSA-N clofarabine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F WDDPHFBMKLOVOX-AYQXTPAHSA-N 0.000 description 2
• 229960000928 clofarabine Drugs 0.000 description 2
• 238000011260 co-administration Methods 0.000 description 2
• 230000015271 coagulation Effects 0.000 description 2
• 238000005345 coagulation Methods 0.000 description 2
• 239000008120 corn starch Substances 0.000 description 2
• 229940097362 cyclodextrins Drugs 0.000 description 2
• STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 2
• 229960002887 deanol Drugs 0.000 description 2
• 229960003603 decitabine Drugs 0.000 description 2
• 206010061428 decreased appetite Diseases 0.000 description 2
• 238000012217 deletion Methods 0.000 description 2
• 230000037430 deletion Effects 0.000 description 2
• 238000013461 design Methods 0.000 description 2
• 229910052805 deuterium Inorganic materials 0.000 description 2
• 235000014113 dietary fatty acids Nutrition 0.000 description 2
• 238000007908 dry granulation Methods 0.000 description 2
• 238000000132 electrospray ionisation Methods 0.000 description 2
• 230000000925 erythroid effect Effects 0.000 description 2
• 238000002474 experimental method Methods 0.000 description 2
• 239000000194 fatty acid Substances 0.000 description 2
• 229930195729 fatty acid Natural products 0.000 description 2
• 150000004665 fatty acids Chemical class 0.000 description 2
• 238000000684 flow cytometry Methods 0.000 description 2
• 239000012530 fluid Substances 0.000 description 2
• 235000013305 food Nutrition 0.000 description 2
• 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 2
• 125000005456 glyceride group Chemical group 0.000 description 2
• LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 2
• 238000004128 high performance liquid chromatography Methods 0.000 description 2
• 108010051779 histone H3 trimethyl Lys4 Proteins 0.000 description 2
• 239000000710 homodimer Substances 0.000 description 2
• 102000012084 human isocitrate dehydrogenase 2 Human genes 0.000 description 2
• 108010036396 human isocitrate dehydrogenase 2 Proteins 0.000 description 2
• 230000036571 hydration Effects 0.000 description 2
• 238000006703 hydration reaction Methods 0.000 description 2
• 229910052739 hydrogen Inorganic materials 0.000 description 2
• 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
• 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
• 229960003943 hypromellose Drugs 0.000 description 2
• 229960000908 idarubicin Drugs 0.000 description 2
• 238000000338 in vitro Methods 0.000 description 2
• 208000015181 infectious disease Diseases 0.000 description 2
• 238000001802 infusion Methods 0.000 description 2
• 229940011051 isopropyl acetate Drugs 0.000 description 2
• GWYFCOCPABKNJV-UHFFFAOYSA-N isovaleric acid Chemical compound CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 description 2
• 239000008101 lactose Substances 0.000 description 2
• 206010024378 leukocytosis Diseases 0.000 description 2
• 230000000670 limiting effect Effects 0.000 description 2
• 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 2
• 238000012423 maintenance Methods 0.000 description 2
• 238000004949 mass spectrometry Methods 0.000 description 2
• 238000001819 mass spectrum Methods 0.000 description 2
• 238000002844 melting Methods 0.000 description 2
• 230000008018 melting Effects 0.000 description 2
• 230000002503 metabolic effect Effects 0.000 description 2
• 229910021645 metal ion Inorganic materials 0.000 description 2
• OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Natural products OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 2
• YGIBQSRKOCQJSO-UHFFFAOYSA-N methanol methyl 6-(trifluoromethyl)pyridine-2-carboxylate Chemical compound CO.COC(=O)c1cccc(n1)C(F)(F)F YGIBQSRKOCQJSO-UHFFFAOYSA-N 0.000 description 2
• 239000002480 mineral oil Substances 0.000 description 2
• 235000010446 mineral oil Nutrition 0.000 description 2
• 230000002438 mitochondrial effect Effects 0.000 description 2
• 208000030454 monosomy Diseases 0.000 description 2
• 210000001167 myeloblast Anatomy 0.000 description 2
• 208000016586 myelodysplastic syndrome with excess blasts Diseases 0.000 description 2
• 208000012846 myelodysplastic syndrome with excess blasts-1 Diseases 0.000 description 2
• 208000012847 myelodysplastic syndrome with excess blasts-2 Diseases 0.000 description 2
• 230000008693 nausea Effects 0.000 description 2
• 239000000346 nonvolatile oil Substances 0.000 description 2
• 239000002773 nucleotide Substances 0.000 description 2
• 125000003729 nucleotide group Chemical group 0.000 description 2
• 239000003921 oil Substances 0.000 description 2
• 235000019198 oils Nutrition 0.000 description 2
• 238000005895 oxidative decarboxylation reaction Methods 0.000 description 2
• 230000002093 peripheral effect Effects 0.000 description 2
• UHZYTMXLRWXGPK-UHFFFAOYSA-N phosphorus pentachloride Chemical compound ClP(Cl)(Cl)(Cl)Cl UHZYTMXLRWXGPK-UHFFFAOYSA-N 0.000 description 2
• 229920000136 polysorbate Polymers 0.000 description 2
• OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 2
• 238000009597 pregnancy test Methods 0.000 description 2
• 238000012545 processing Methods 0.000 description 2
• 239000000047 product Substances 0.000 description 2
• LOUPRKONTZGTKE-LHHVKLHASA-N quinidine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@H]2[C@@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-LHHVKLHASA-N 0.000 description 2
• 230000001850 reproductive effect Effects 0.000 description 2
• 201000004193 respiratory failure Diseases 0.000 description 2
• 238000012552 review Methods 0.000 description 2
• 150000003384 small molecules Chemical class 0.000 description 2
• 239000011734 sodium Substances 0.000 description 2
• 229910000029 sodium carbonate Inorganic materials 0.000 description 2
• 235000017550 sodium carbonate Nutrition 0.000 description 2
• 239000011780 sodium chloride Substances 0.000 description 2
• 229910052938 sodium sulfate Inorganic materials 0.000 description 2
• 235000011152 sodium sulphate Nutrition 0.000 description 2
• 238000002336 sorption--desorption measurement Methods 0.000 description 2
• 238000004611 spectroscopical analysis Methods 0.000 description 2
• 238000007619 statistical method Methods 0.000 description 2
• KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 2
• 239000004094 surface-active agent Substances 0.000 description 2
• 238000001356 surgical procedure Methods 0.000 description 2
• 239000000375 suspending agent Substances 0.000 description 2
• 230000002459 sustained effect Effects 0.000 description 2
• ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
• 229960002784 thioridazine Drugs 0.000 description 2
• 206010043554 thrombocytopenia Diseases 0.000 description 2
• 238000004448 titration Methods 0.000 description 2
• 238000011200 topical administration Methods 0.000 description 2
• 230000000699 topical effect Effects 0.000 description 2
• 230000005945 translocation Effects 0.000 description 2
• 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 2
• 231100000402 unacceptable toxicity Toxicity 0.000 description 2
• 238000002562 urinalysis Methods 0.000 description 2
• UHTHHESEBZOYNR-UHFFFAOYSA-N vandetanib Chemical compound COC1=CC(C(/N=CN2)=N/C=3C(=CC(Br)=CC=3)F)=C2C=C1OCC1CCN(C)CC1 UHTHHESEBZOYNR-UHFFFAOYSA-N 0.000 description 2
• 235000013311 vegetables Nutrition 0.000 description 2
• 230000002861 ventricular Effects 0.000 description 2
• 210000005048 vimentin Anatomy 0.000 description 2
• 239000003643 water by type Substances 0.000 description 2
• 230000003442 weekly effect Effects 0.000 description 2
• HBUBKKRHXORPQB-FJFJXFQQSA-N (2R,3S,4S,5R)-2-(6-amino-2-fluoro-9-purinyl)-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O HBUBKKRHXORPQB-FJFJXFQQSA-N 0.000 description 1
• ZWHOTPNCEFWATE-AWEZNQCLSA-N (3S)-3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy-N-phenylpyrrolidine-1-carboxamide Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)O[C@@H]1CN(CC1)C(=O)NC1=CC=CC=C1 ZWHOTPNCEFWATE-AWEZNQCLSA-N 0.000 description 1
• WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
• WSEQXVZVJXJVFP-HXUWFJFHSA-N (R)-citalopram Chemical compound C1([C@@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-HXUWFJFHSA-N 0.000 description 1
• GMHKMTDVRCWUDX-LBPRGKRZSA-N (S)-Mephenytoin Chemical compound C=1C=CC=CC=1[C@]1(CC)NC(=O)N(C)C1=O GMHKMTDVRCWUDX-LBPRGKRZSA-N 0.000 description 1
• WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 description 1
• 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
• RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
• VVJYUAYZJAKGRQ-UHFFFAOYSA-N 1-[4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C(O)C1 VVJYUAYZJAKGRQ-UHFFFAOYSA-N 0.000 description 1
• VSNHCAURESNICA-NJFSPNSNSA-N 1-oxidanylurea Chemical compound N[14C](=O)NO VSNHCAURESNICA-NJFSPNSNSA-N 0.000 description 1
• IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
• CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
• FSPQCTGGIANIJZ-UHFFFAOYSA-N 2-[[(3,4-dimethoxyphenyl)-oxomethyl]amino]-4,5,6,7-tetrahydro-1-benzothiophene-3-carboxamide Chemical compound C1=C(OC)C(OC)=CC=C1C(=O)NC1=C(C(N)=O)C(CCCC2)=C2S1 FSPQCTGGIANIJZ-UHFFFAOYSA-N 0.000 description 1
• LEACJMVNYZDSKR-UHFFFAOYSA-N 2-octyldodecan-1-ol Chemical compound CCCCCCCCCCC(CO)CCCCCCCC LEACJMVNYZDSKR-UHFFFAOYSA-N 0.000 description 1
• KPGXRSRHYNQIFN-UHFFFAOYSA-N 2-oxoglutaric acid Chemical compound OC(=O)CCC(=O)C(O)=O KPGXRSRHYNQIFN-UHFFFAOYSA-N 0.000 description 1
• LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
• SHBHYINHXNTBRP-UHFFFAOYSA-N 3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy-N-(2-methylsulfonylethyl)benzamide Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC=1C=C(C(=O)NCCS(=O)(=O)C)C=CC=1 SHBHYINHXNTBRP-UHFFFAOYSA-N 0.000 description 1
• NMUSYJAQQFHJEW-UHFFFAOYSA-N 5-Azacytidine Natural products O=C1N=C(N)N=CN1C1C(O)C(O)C(CO)O1 NMUSYJAQQFHJEW-UHFFFAOYSA-N 0.000 description 1
• NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 description 1
• USSIQXCVUWKGNF-UHFFFAOYSA-N 6-(dimethylamino)-4,4-diphenylheptan-3-one Chemical compound C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 USSIQXCVUWKGNF-UHFFFAOYSA-N 0.000 description 1
• STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
• QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
• GJCOSYZMQJWQCA-UHFFFAOYSA-N 9H-xanthene Chemical compound C1=CC=C2CC3=CC=CC=C3OC2=C1 GJCOSYZMQJWQCA-UHFFFAOYSA-N 0.000 description 1
• ITPDYQOUSLNIHG-UHFFFAOYSA-N Amiodarone hydrochloride Chemical compound [Cl-].CCCCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(I)=C(OCC[NH+](CC)CC)C(I)=C1 ITPDYQOUSLNIHG-UHFFFAOYSA-N 0.000 description 1
• NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
• 206010073478 Anaplastic large-cell lymphoma Diseases 0.000 description 1
• 108010003415 Aspartate Aminotransferases Proteins 0.000 description 1
• 102000004625 Aspartate Aminotransferases Human genes 0.000 description 1
• 108010017384 Blood Proteins Proteins 0.000 description 1
• 102000004506 Blood Proteins Human genes 0.000 description 1
• 208000019838 Blood disease Diseases 0.000 description 1
• 206010065553 Bone marrow failure Diseases 0.000 description 1
• 241000219198 Brassica Species 0.000 description 1
• 235000003351 Brassica cretica Nutrition 0.000 description 1
• 244000178993 Brassica juncea Species 0.000 description 1
• 235000011332 Brassica juncea Nutrition 0.000 description 1
• 240000007124 Brassica oleracea Species 0.000 description 1
• 235000003899 Brassica oleracea var acephala Nutrition 0.000 description 1
• 235000011299 Brassica oleracea var botrytis Nutrition 0.000 description 1
• 235000004221 Brassica oleracea var gemmifera Nutrition 0.000 description 1
• 235000017647 Brassica oleracea var italica Nutrition 0.000 description 1
• 244000064816 Brassica oleracea var. acephala Species 0.000 description 1
• 240000003259 Brassica oleracea var. botrytis Species 0.000 description 1
• 244000308368 Brassica oleracea var. gemmifera Species 0.000 description 1
• 244000304217 Brassica oleracea var. gongylodes Species 0.000 description 1
• 235000003343 Brassica rupestris Nutrition 0.000 description 1
• 206010006482 Bronchospasm Diseases 0.000 description 1
• 208000011691 Burkitt lymphomas Diseases 0.000 description 1
• 101100342337 Caenorhabditis elegans klf-1 gene Proteins 0.000 description 1
• 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
• 208000017667 Chronic Disease Diseases 0.000 description 1
• 244000183685 Citrus aurantium Species 0.000 description 1
• 235000007716 Citrus aurantium Nutrition 0.000 description 1
• 235000005976 Citrus sinensis Nutrition 0.000 description 1
• 208000032170 Congenital Abnormalities Diseases 0.000 description 1
• 206010010356 Congenital anomaly Diseases 0.000 description 1
• 206010010904 Convulsion Diseases 0.000 description 1
• 206010011224 Cough Diseases 0.000 description 1
• 108010020070 Cytochrome P-450 CYP2B6 Proteins 0.000 description 1
• 108010000543 Cytochrome P-450 CYP2C9 Proteins 0.000 description 1
• 208000000130 Cytochrome P-450 CYP3A Inducers Diseases 0.000 description 1
• 102100038739 Cytochrome P450 2B6 Human genes 0.000 description 1
• 102100029358 Cytochrome P450 2C9 Human genes 0.000 description 1
• 102100021704 Cytochrome P450 2D6 Human genes 0.000 description 1
• FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
• 230000007067 DNA methylation Effects 0.000 description 1
• 238000001712 DNA sequencing Methods 0.000 description 1
• LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 description 1
• 206010013654 Drug abuse Diseases 0.000 description 1
• 206010013710 Drug interaction Diseases 0.000 description 1
• 206010058314 Dysplasia Diseases 0.000 description 1
• 241000792859 Enema Species 0.000 description 1
• 208000031637 Erythroblastic Acute Leukemia Diseases 0.000 description 1
• 208000036566 Erythroleukaemia Diseases 0.000 description 1
• 102000003951 Erythropoietin Human genes 0.000 description 1
• 102100031939 Erythropoietin Human genes 0.000 description 1
• 108090000394 Erythropoietin Proteins 0.000 description 1
• 208000010201 Exanthema Diseases 0.000 description 1
• 208000002633 Febrile Neutropenia Diseases 0.000 description 1
• DJBNUMBKLMJRSA-UHFFFAOYSA-N Flecainide Chemical compound FC(F)(F)COC1=CC=C(OCC(F)(F)F)C(C(=O)NCC2NCCCC2)=C1 DJBNUMBKLMJRSA-UHFFFAOYSA-N 0.000 description 1
• 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
• 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 1
• 239000004471 Glycine Substances 0.000 description 1
• 206010066476 Haematological malignancy Diseases 0.000 description 1
• 206010018910 Haemolysis Diseases 0.000 description 1
• FOHHNHSLJDZUGQ-VWLOTQADSA-N Halofantrine Chemical compound FC(F)(F)C1=CC=C2C([C@@H](O)CCN(CCCC)CCCC)=CC3=C(Cl)C=C(Cl)C=C3C2=C1 FOHHNHSLJDZUGQ-VWLOTQADSA-N 0.000 description 1
• 241000282412 Homo Species 0.000 description 1
• 101000945515 Homo sapiens CCAAT/enhancer-binding protein alpha Proteins 0.000 description 1
• 101000745711 Homo sapiens Cytochrome P450 3A4 Proteins 0.000 description 1
• 101100452039 Homo sapiens IDH2 gene Proteins 0.000 description 1
• 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 1
• 102000008100 Human Serum Albumin Human genes 0.000 description 1
• 108091006905 Human Serum Albumin Proteins 0.000 description 1
• VSNHCAURESNICA-UHFFFAOYSA-N Hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 description 1
• 244000141009 Hypericum perforatum Species 0.000 description 1
• 235000017309 Hypericum perforatum Nutrition 0.000 description 1
• ALOBUEHUHMBRLE-UHFFFAOYSA-N Ibutilide Chemical compound CCCCCCCN(CC)CCCC(O)C1=CC=C(NS(C)(=O)=O)C=C1 ALOBUEHUHMBRLE-UHFFFAOYSA-N 0.000 description 1
• 238000012404 In vitro experiment Methods 0.000 description 1
• 206010062717 Increased upper airway secretion Diseases 0.000 description 1
• 108010044467 Isoenzymes Proteins 0.000 description 1
• RRHGJUQNOFWUDK-UHFFFAOYSA-N Isoprene Chemical compound CC(=C)C=C RRHGJUQNOFWUDK-UHFFFAOYSA-N 0.000 description 1
• 102100022248 Krueppel-like factor 1 Human genes 0.000 description 1
• WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
• 239000002118 L01XE12 - Vandetanib Substances 0.000 description 1
• 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 description 1
• 208000032004 Large-Cell Anaplastic Lymphoma Diseases 0.000 description 1
• 229910013470 LiC1 Inorganic materials 0.000 description 1
• 229930195725 Mannitol Natural products 0.000 description 1
• 208000025205 Mantle-Cell Lymphoma Diseases 0.000 description 1
• 108010047230 Member 1 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 description 1
• 241000699666 Mus <mouse, genus> Species 0.000 description 1
• 241000699660 Mus musculus Species 0.000 description 1
• 108010021466 Mutant Proteins Proteins 0.000 description 1
• 102000008300 Mutant Proteins Human genes 0.000 description 1
• 235000017879 Nasturtium officinale Nutrition 0.000 description 1
• 240000005407 Nasturtium officinale Species 0.000 description 1
• 206010030124 Oedema peripheral Diseases 0.000 description 1
• 239000005642 Oleic acid Substances 0.000 description 1
• ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
• 229910019142 PO4 Inorganic materials 0.000 description 1
• 229930012538 Paclitaxel Natural products 0.000 description 1
• 208000010995 Partial deletion of the long arm of chromosome 11 Diseases 0.000 description 1
• CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 description 1
• 239000004698 Polyethylene Substances 0.000 description 1
• 229920001214 Polysorbate 60 Polymers 0.000 description 1
• 206010036524 Precursor B-lymphoblastic lymphomas Diseases 0.000 description 1
• 108010007568 Protamines Proteins 0.000 description 1
• 102000007327 Protamines Human genes 0.000 description 1
• 102000012751 Pyruvate Dehydrogenase Complex Human genes 0.000 description 1
• 108010090051 Pyruvate Dehydrogenase Complex Proteins 0.000 description 1
• 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 1
• 238000011579 SCID mouse model Methods 0.000 description 1
• 244000061456 Solanum tuberosum Species 0.000 description 1
• 235000002595 Solanum tuberosum Nutrition 0.000 description 1
• HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
• 208000020982 T-lymphoblastic lymphoma Diseases 0.000 description 1
• GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
• 238000008050 Total Bilirubin Reagent Methods 0.000 description 1
• 108091023040 Transcription factor Proteins 0.000 description 1
• 102000040945 Transcription factor Human genes 0.000 description 1
• YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
• REAYFGLASQTHKB-UHFFFAOYSA-N [2-[3-(1H-pyrazol-4-yl)phenoxy]-6-(trifluoromethyl)pyridin-4-yl]methanamine Chemical compound N1N=CC(=C1)C=1C=C(OC2=NC(=CC(=C2)CN)C(F)(F)F)C=CC=1 REAYFGLASQTHKB-UHFFFAOYSA-N 0.000 description 1
• IKWTVSLWAPBBKU-UHFFFAOYSA-N a1010_sial Chemical compound O=[As]O[As]=O IKWTVSLWAPBBKU-UHFFFAOYSA-N 0.000 description 1
• 229940124532 absorption promoter Drugs 0.000 description 1
• DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
• IYKJEILNJZQJPU-UHFFFAOYSA-N acetic acid;butanedioic acid Chemical compound CC(O)=O.OC(=O)CCC(O)=O IYKJEILNJZQJPU-UHFFFAOYSA-N 0.000 description 1
• ZUAAPNNKRHMPKG-UHFFFAOYSA-N acetic acid;butanedioic acid;methanol;propane-1,2-diol Chemical compound OC.CC(O)=O.CC(O)CO.OC(=O)CCC(O)=O ZUAAPNNKRHMPKG-UHFFFAOYSA-N 0.000 description 1
• 239000002253 acid Substances 0.000 description 1
• 150000007513 acids Chemical class 0.000 description 1
• YBCVMFKXIKNREZ-UHFFFAOYSA-N acoh acetic acid Chemical compound CC(O)=O.CC(O)=O YBCVMFKXIKNREZ-UHFFFAOYSA-N 0.000 description 1
• 239000013543 active substance Substances 0.000 description 1
• 230000009056 active transport Effects 0.000 description 1
• 208000021841 acute erythroid leukemia Diseases 0.000 description 1
• 230000000735 allogeneic effect Effects 0.000 description 1
• PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
• CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
• 229940063655 aluminum stearate Drugs 0.000 description 1
• 229960005260 amiodarone Drugs 0.000 description 1
• 235000019270 ammonium chloride Nutrition 0.000 description 1
• 210000004381 amniotic fluid Anatomy 0.000 description 1
• 230000003321 amplification Effects 0.000 description 1
• 229940035676 analgesics Drugs 0.000 description 1
• 208000007502 anemia Diseases 0.000 description 1
• 239000000730 antalgic agent Substances 0.000 description 1
• 239000003242 anti bacterial agent Substances 0.000 description 1
• 230000003466 anti-cipated effect Effects 0.000 description 1
• 230000003474 anti-emetic effect Effects 0.000 description 1
• 230000002924 anti-infective effect Effects 0.000 description 1
• 230000000118 anti-neoplastic effect Effects 0.000 description 1
• 230000001754 anti-pyretic effect Effects 0.000 description 1
• 239000012296 anti-solvent Substances 0.000 description 1
• 230000000259 anti-tumor effect Effects 0.000 description 1
• 229940088710 antibiotic agent Drugs 0.000 description 1
• 229940125683 antiemetic agent Drugs 0.000 description 1
• 239000002111 antiemetic agent Substances 0.000 description 1
• 229960005475 antiinfective agent Drugs 0.000 description 1
• 239000002221 antipyretic Substances 0.000 description 1
• 229940125716 antipyretic agent Drugs 0.000 description 1
• 229960002594 arsenic trioxide Drugs 0.000 description 1
• GOLCXWYRSKYTSP-UHFFFAOYSA-N arsenic trioxide Inorganic materials O1[As]2O[As]1O2 GOLCXWYRSKYTSP-UHFFFAOYSA-N 0.000 description 1
• 238000003556 assay Methods 0.000 description 1
• GXDALQBWZGODGZ-UHFFFAOYSA-N astemizole Chemical compound C1=CC(OC)=CC=C1CCN1CCC(NC=2N(C3=CC=CC=C3N=2)CC=2C=CC(F)=CC=2)CC1 GXDALQBWZGODGZ-UHFFFAOYSA-N 0.000 description 1
• 229960002756 azacitidine Drugs 0.000 description 1
• 229960004099 azithromycin Drugs 0.000 description 1
• MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 description 1
• 235000015241 bacon Nutrition 0.000 description 1
• 239000002585 base Substances 0.000 description 1
• 235000013871 bee wax Nutrition 0.000 description 1
• 239000012166 beeswax Substances 0.000 description 1
• UIEATEWHFDRYRU-UHFFFAOYSA-N bepridil Chemical compound C1CCCN1C(COCC(C)C)CN(C=1C=CC=CC=1)CC1=CC=CC=C1 UIEATEWHFDRYRU-UHFFFAOYSA-N 0.000 description 1
• 229960003665 bepridil Drugs 0.000 description 1
• 235000013361 beverage Nutrition 0.000 description 1
• 230000007698 birth defect Effects 0.000 description 1
• QKSKPIVNLNLAAV-UHFFFAOYSA-N bis(2-chloroethyl) sulfide Chemical compound ClCCSCCCl QKSKPIVNLNLAAV-UHFFFAOYSA-N 0.000 description 1
• 238000004159 blood analysis Methods 0.000 description 1
• 231100001015 blood dyscrasias Toxicity 0.000 description 1
• 238000010241 blood sampling Methods 0.000 description 1
• 238000009583 bone marrow aspiration Methods 0.000 description 1
• 210000004556 brain Anatomy 0.000 description 1
• 229910052799 carbon Inorganic materials 0.000 description 1
• 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
• 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
• 239000012876 carrier material Substances 0.000 description 1
• 239000004359 castor oil Substances 0.000 description 1
• 235000019438 castor oil Nutrition 0.000 description 1
• 230000015556 catabolic process Effects 0.000 description 1
• 230000001364 causal effect Effects 0.000 description 1
• 239000002771 cell marker Substances 0.000 description 1
• 235000010980 cellulose Nutrition 0.000 description 1
• 229920002678 cellulose Polymers 0.000 description 1
• 239000001913 cellulose Substances 0.000 description 1
• 210000002939 cerumen Anatomy 0.000 description 1
• 210000003756 cervix mucus Anatomy 0.000 description 1
• 229940081733 cetearyl alcohol Drugs 0.000 description 1
• PBAYDYUZOSNJGU-UHFFFAOYSA-N chelidonic acid Natural products OC(=O)C1=CC(=O)C=C(C(O)=O)O1 PBAYDYUZOSNJGU-UHFFFAOYSA-N 0.000 description 1
• HEDRZPFGACZZDS-UHFFFAOYSA-N chloroform Substances ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 1
• 229960003677 chloroquine Drugs 0.000 description 1
• WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 description 1
• ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 description 1
• 229960001076 chlorpromazine Drugs 0.000 description 1
• 210000000349 chromosome Anatomy 0.000 description 1
• 208000015319 chromosome 12p deletion Diseases 0.000 description 1
• 230000001684 chronic effect Effects 0.000 description 1
• 210000004913 chyme Anatomy 0.000 description 1
• LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 1
• DCSUBABJRXZOMT-IRLDBZIGSA-N cisapride Chemical compound C([C@@H]([C@@H](CC1)NC(=O)C=2C(=CC(N)=C(Cl)C=2)OC)OC)N1CCCOC1=CC=C(F)C=C1 DCSUBABJRXZOMT-IRLDBZIGSA-N 0.000 description 1
• 229960005132 cisapride Drugs 0.000 description 1
• DCSUBABJRXZOMT-UHFFFAOYSA-N cisapride Natural products C1CC(NC(=O)C=2C(=CC(N)=C(Cl)C=2)OC)C(OC)CN1CCCOC1=CC=C(F)C=C1 DCSUBABJRXZOMT-UHFFFAOYSA-N 0.000 description 1
• 229960001653 citalopram Drugs 0.000 description 1
• 229960002626 clarithromycin Drugs 0.000 description 1
• AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 description 1
• 229940110456 cocoa butter Drugs 0.000 description 1
• 235000019868 cocoa butter Nutrition 0.000 description 1
• 239000008119 colloidal silica Substances 0.000 description 1
• 239000003086 colorant Substances 0.000 description 1
• 238000005056 compaction Methods 0.000 description 1
• 238000012790 confirmation Methods 0.000 description 1
• 238000009108 consolidation therapy Methods 0.000 description 1
• 238000010276 construction Methods 0.000 description 1
• 230000036461 convulsion Effects 0.000 description 1
• 238000001816 cooling Methods 0.000 description 1
• 230000002596 correlated effect Effects 0.000 description 1
• 230000000875 corresponding effect Effects 0.000 description 1
• 239000003246 corticosteroid Substances 0.000 description 1
• 229960001334 corticosteroids Drugs 0.000 description 1
• 239000006071 cream Substances 0.000 description 1
• 239000002178 crystalline material Substances 0.000 description 1
• 230000001086 cytosolic effect Effects 0.000 description 1
• 229960000975 daunorubicin Drugs 0.000 description 1
• DEZRYPDIMOWBDS-UHFFFAOYSA-N dcm dichloromethane Chemical compound ClCCl.ClCCl DEZRYPDIMOWBDS-UHFFFAOYSA-N 0.000 description 1
• 230000017858 demethylation Effects 0.000 description 1
• 238000010520 demethylation reaction Methods 0.000 description 1
• 235000005911 diet Nutrition 0.000 description 1
• 230000037213 diet Effects 0.000 description 1
• 206010012818 diffuse large B-cell lymphoma Diseases 0.000 description 1
• LTMHDMANZUZIPE-PUGKRICDSA-N digoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 description 1
• 229960005156 digoxin Drugs 0.000 description 1
• LTMHDMANZUZIPE-UHFFFAOYSA-N digoxine Natural products C1C(O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)C(O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O LTMHDMANZUZIPE-UHFFFAOYSA-N 0.000 description 1
• 150000004683 dihydrates Chemical class 0.000 description 1
• 238000010790 dilution Methods 0.000 description 1
• 239000012895 dilution Substances 0.000 description 1
• FSBVERYRVPGNGG-UHFFFAOYSA-N dimagnesium dioxido-bis[[oxido(oxo)silyl]oxy]silane hydrate Chemical compound O.[Mg+2].[Mg+2].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O FSBVERYRVPGNGG-UHFFFAOYSA-N 0.000 description 1
• 239000000539 dimer Substances 0.000 description 1
• UXGNZZKBCMGWAZ-UHFFFAOYSA-N dimethylformamide dmf Chemical compound CN(C)C=O.CN(C)C=O UXGNZZKBCMGWAZ-UHFFFAOYSA-N 0.000 description 1
• ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
• 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
• 235000019797 dipotassium phosphate Nutrition 0.000 description 1
• 230000008034 disappearance Effects 0.000 description 1
• BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
• UVTNFZQICZKOEM-UHFFFAOYSA-N disopyramide Chemical compound C=1C=CC=NC=1C(C(N)=O)(CCN(C(C)C)C(C)C)C1=CC=CC=C1 UVTNFZQICZKOEM-UHFFFAOYSA-N 0.000 description 1
• 229960001066 disopyramide Drugs 0.000 description 1
• 239000006185 dispersion Substances 0.000 description 1
• 238000010494 dissociation reaction Methods 0.000 description 1
• 230000005593 dissociations Effects 0.000 description 1
• 208000002173 dizziness Diseases 0.000 description 1
• CETRZFQIITUQQL-UHFFFAOYSA-N dmso dimethylsulfoxide Chemical compound CS(C)=O.CS(C)=O CETRZFQIITUQQL-UHFFFAOYSA-N 0.000 description 1
• IXTMWRCNAAVVAI-UHFFFAOYSA-N dofetilide Chemical compound C=1C=C(NS(C)(=O)=O)C=CC=1CCN(C)CCOC1=CC=C(NS(C)(=O)=O)C=C1 IXTMWRCNAAVVAI-UHFFFAOYSA-N 0.000 description 1
• 229960002994 dofetilide Drugs 0.000 description 1
• FGXWKSZFVQUSTL-UHFFFAOYSA-N domperidone Chemical compound C12=CC=CC=C2NC(=O)N1CCCN(CC1)CCC1N1C2=CC=C(Cl)C=C2NC1=O FGXWKSZFVQUSTL-UHFFFAOYSA-N 0.000 description 1
• 229960001253 domperidone Drugs 0.000 description 1
• RMEDXOLNCUSCGS-UHFFFAOYSA-N droperidol Chemical compound C1=CC(F)=CC=C1C(=O)CCCN1CC=C(N2C(NC3=CC=CC=C32)=O)CC1 RMEDXOLNCUSCGS-UHFFFAOYSA-N 0.000 description 1
• 229960000394 droperidol Drugs 0.000 description 1
• 239000000890 drug combination Substances 0.000 description 1
• 238000012377 drug delivery Methods 0.000 description 1
• 235000013601 eggs Nutrition 0.000 description 1
• 239000003792 electrolyte Substances 0.000 description 1
• 230000008030 elimination Effects 0.000 description 1
• 238000003379 elimination reaction Methods 0.000 description 1
• 230000001804 emulsifying effect Effects 0.000 description 1
• 239000008387 emulsifying waxe Substances 0.000 description 1
• DYLUUSLLRIQKOE-UHFFFAOYSA-N enasidenib Chemical compound N=1C(C=2N=C(C=CC=2)C(F)(F)F)=NC(NCC(C)(O)C)=NC=1NC1=CC=NC(C(F)(F)F)=C1 DYLUUSLLRIQKOE-UHFFFAOYSA-N 0.000 description 1
• 239000007920 enema Substances 0.000 description 1
• 229940095399 enema Drugs 0.000 description 1
• 239000003623 enhancer Substances 0.000 description 1
• 230000007613 environmental effect Effects 0.000 description 1
• 108010089558 erythroid Kruppel-like factor Proteins 0.000 description 1
• 229960003276 erythromycin Drugs 0.000 description 1
• 230000010437 erythropoiesis Effects 0.000 description 1
• 229940105423 erythropoietin Drugs 0.000 description 1
• WSEQXVZVJXJVFP-FQEVSTJZSA-N escitalopram Chemical compound C1([C@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-FQEVSTJZSA-N 0.000 description 1
• 229960004341 escitalopram Drugs 0.000 description 1
• BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
• CHDFNIZLAAFFPX-UHFFFAOYSA-N ethoxyethane;oxolane Chemical compound CCOCC.C1CCOC1 CHDFNIZLAAFFPX-UHFFFAOYSA-N 0.000 description 1
• 238000010228 ex vivo assay Methods 0.000 description 1
• 201000005884 exanthem Diseases 0.000 description 1
• 230000029142 excretion Effects 0.000 description 1
• 239000008383 extra-granule composition Substances 0.000 description 1
• 210000003722 extracellular fluid Anatomy 0.000 description 1
• 206010016256 fatigue Diseases 0.000 description 1
• 235000019197 fats Nutrition 0.000 description 1
• 230000002349 favourable effect Effects 0.000 description 1
• 210000003754 fetus Anatomy 0.000 description 1
• 230000027950 fever generation Effects 0.000 description 1
• 239000000706 filtrate Substances 0.000 description 1
• 239000000796 flavoring agent Substances 0.000 description 1
• 229960000449 flecainide Drugs 0.000 description 1
• 239000011888 foil Substances 0.000 description 1
• 201000003444 follicular lymphoma Diseases 0.000 description 1
• 239000012634 fragment Substances 0.000 description 1
• 235000015203 fruit juice Nutrition 0.000 description 1
• 238000004817 gas chromatography Methods 0.000 description 1
• 208000030304 gastrointestinal bleeding Diseases 0.000 description 1
• 210000001035 gastrointestinal tract Anatomy 0.000 description 1
• 238000007429 general method Methods 0.000 description 1
• 230000023266 generation of precursor metabolites and energy Effects 0.000 description 1
• 239000011521 glass Substances 0.000 description 1
• 230000001434 glomerular Effects 0.000 description 1
• 229930195712 glutamate Natural products 0.000 description 1
• JFCQEDHGNNZCLN-UHFFFAOYSA-N glutaric acid Chemical compound OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 1
• ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
• 229960002449 glycine Drugs 0.000 description 1
• 235000015201 grapefruit juice Nutrition 0.000 description 1
• 235000021384 green leafy vegetables Nutrition 0.000 description 1
• 239000003102 growth factor Substances 0.000 description 1
• 231100000226 haematotoxicity Toxicity 0.000 description 1
• 229960003242 halofantrine Drugs 0.000 description 1
• 229960003878 haloperidol Drugs 0.000 description 1
• 230000003862 health status Effects 0.000 description 1
• 230000004217 heart function Effects 0.000 description 1
• 208000014951 hematologic disease Diseases 0.000 description 1
• 230000006842 hematologic response Effects 0.000 description 1
• 208000018706 hematopoietic system disease Diseases 0.000 description 1
• 230000008588 hemolysis Effects 0.000 description 1
• 239000000833 heterodimer Substances 0.000 description 1
• 102000044284 human CYP3A4 Human genes 0.000 description 1
• 235000020256 human milk Nutrition 0.000 description 1
• 210000004251 human milk Anatomy 0.000 description 1
• VEXZGXHMUGYJMC-UHFFFAOYSA-N hydrochloric acid Substances Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
• 239000001257 hydrogen Substances 0.000 description 1
• 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
• 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
• 229960001330 hydroxycarbamide Drugs 0.000 description 1
• 229960004053 ibutilide Drugs 0.000 description 1
• 239000012535 impurity Substances 0.000 description 1
• 239000000411 inducer Substances 0.000 description 1
• 238000011419 induction treatment Methods 0.000 description 1
• 229940102223 injectable solution Drugs 0.000 description 1
• 229940102213 injectable suspension Drugs 0.000 description 1
• 238000011081 inoculation Methods 0.000 description 1
• 239000008382 intra-granule composition Substances 0.000 description 1
• 238000001361 intraarterial administration Methods 0.000 description 1
• 230000037041 intracellular level Effects 0.000 description 1
• 238000007917 intracranial administration Methods 0.000 description 1
• 238000007918 intramuscular administration Methods 0.000 description 1
• 238000007919 intrasynovial administration Methods 0.000 description 1
• 238000007913 intrathecal administration Methods 0.000 description 1
• 238000001990 intravenous administration Methods 0.000 description 1
• 150000002500 ions Chemical class 0.000 description 1
• 238000002955 isolation Methods 0.000 description 1
• QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
• 230000003907 kidney function Effects 0.000 description 1
• 235000010445 lecithin Nutrition 0.000 description 1
• 239000000787 lecithin Substances 0.000 description 1
• 229940067606 lecithin Drugs 0.000 description 1
• 230000003902 lesion Effects 0.000 description 1
• XBMIVRRWGCYBTQ-AVRDEDQJSA-N levacetylmethadol Chemical group C=1C=CC=CC=1C(C[C@H](C)N(C)C)([C@@H](OC(C)=O)CC)C1=CC=CC=C1 XBMIVRRWGCYBTQ-AVRDEDQJSA-N 0.000 description 1
• 229940087121 levomethadyl Drugs 0.000 description 1
• QDLAGTHXVHQKRE-UHFFFAOYSA-N lichenxanthone Natural products COC1=CC(O)=C2C(=O)C3=C(C)C=C(OC)C=C3OC2=C1 QDLAGTHXVHQKRE-UHFFFAOYSA-N 0.000 description 1
• 230000003908 liver function Effects 0.000 description 1
• 230000007774 longterm Effects 0.000 description 1
• 239000006210 lotion Substances 0.000 description 1
• 239000000314 lubricant Substances 0.000 description 1
• 210000002751 lymph Anatomy 0.000 description 1
• 210000002540 macrophage Anatomy 0.000 description 1
• YIXJRHPUWRPCBB-UHFFFAOYSA-N magnesium nitrate Inorganic materials [Mg+2].[O-][N+]([O-])=O.[O-][N+]([O-])=O YIXJRHPUWRPCBB-UHFFFAOYSA-N 0.000 description 1
• 239000000391 magnesium silicate Substances 0.000 description 1
• 235000019793 magnesium trisilicate Nutrition 0.000 description 1
• 229940099273 magnesium trisilicate Drugs 0.000 description 1
• 229910000386 magnesium trisilicate Inorganic materials 0.000 description 1
• 239000000594 mannitol Substances 0.000 description 1
• 235000010355 mannitol Nutrition 0.000 description 1
• 239000003550 marker Substances 0.000 description 1
• 239000011159 matrix material Substances 0.000 description 1
• 230000035800 maturation Effects 0.000 description 1
• 235000013372 meat Nutrition 0.000 description 1
• BCVXHSPFUWZLGQ-UHFFFAOYSA-N mecn acetonitrile Chemical compound CC#N.CC#N BCVXHSPFUWZLGQ-UHFFFAOYSA-N 0.000 description 1
• SLVMESMUVMCQIY-UHFFFAOYSA-N mesoridazine Chemical compound CN1CCCCC1CCN1C2=CC(S(C)=O)=CC=C2SC2=CC=CC=C21 SLVMESMUVMCQIY-UHFFFAOYSA-N 0.000 description 1
• 229960000300 mesoridazine Drugs 0.000 description 1
• 238000002705 metabolomic analysis Methods 0.000 description 1
• 230000001431 metabolomic effect Effects 0.000 description 1
• 210000001237 metamyelocyte Anatomy 0.000 description 1
• 229960001797 methadone Drugs 0.000 description 1
• NBTOZLQBSIZIKS-UHFFFAOYSA-N methoxide Chemical compound [O-]C NBTOZLQBSIZIKS-UHFFFAOYSA-N 0.000 description 1
• 229940042472 mineral oil Drugs 0.000 description 1
• 210000003470 mitochondria Anatomy 0.000 description 1
• 238000012544 monitoring process Methods 0.000 description 1
• 150000004682 monohydrates Chemical class 0.000 description 1
• 238000010172 mouse model Methods 0.000 description 1
• FABPRXSRWADJSP-MEDUHNTESA-N moxifloxacin Chemical compound COC1=C(N2C[C@H]3NCCC[C@H]3C2)C(F)=CC(C(C(C(O)=O)=C2)=O)=C1N2C1CC1 FABPRXSRWADJSP-MEDUHNTESA-N 0.000 description 1
• 229960003702 moxifloxacin Drugs 0.000 description 1
• 210000003097 mucus Anatomy 0.000 description 1
• 235000010460 mustard Nutrition 0.000 description 1
• 201000005962 mycosis fungoides Diseases 0.000 description 1
• 230000001400 myeloablative effect Effects 0.000 description 1
• 239000007922 nasal spray Substances 0.000 description 1
• 229910052757 nitrogen Inorganic materials 0.000 description 1
• 231100000344 non-irritating Toxicity 0.000 description 1
• 238000010899 nucleation Methods 0.000 description 1
• 238000003199 nucleic acid amplification method Methods 0.000 description 1
• 238000011580 nude mouse model Methods 0.000 description 1
• GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 1
• 239000002674 ointment Substances 0.000 description 1
• ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
• 239000004006 olive oil Substances 0.000 description 1
• 235000008390 olive oil Nutrition 0.000 description 1
• 230000008520 organization Effects 0.000 description 1
• 230000002018 overexpression Effects 0.000 description 1
• 230000003647 oxidation Effects 0.000 description 1
• 238000007254 oxidation reaction Methods 0.000 description 1
• 229960001592 paclitaxel Drugs 0.000 description 1
• 239000002245 particle Substances 0.000 description 1
• 239000013610 patient sample Substances 0.000 description 1
• XDRYMKDFEDOLFX-UHFFFAOYSA-N pentamidine Chemical compound C1=CC(C(=N)N)=CC=C1OCCCCCOC1=CC=C(C(N)=N)C=C1 XDRYMKDFEDOLFX-UHFFFAOYSA-N 0.000 description 1
• 229960004448 pentamidine Drugs 0.000 description 1
• 208000033808 peripheral neuropathy Diseases 0.000 description 1
• 230000035699 permeability Effects 0.000 description 1
• 230000002688 persistence Effects 0.000 description 1
• 206010034754 petechiae Diseases 0.000 description 1
• 239000000546 pharmaceutical excipient Substances 0.000 description 1
• 230000000144 pharmacologic effect Effects 0.000 description 1
• 229960002036 phenytoin Drugs 0.000 description 1
• 208000026435 phlegm Diseases 0.000 description 1
• 235000021317 phosphate Nutrition 0.000 description 1
• 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
• YVUQSNJEYSNKRX-UHFFFAOYSA-N pimozide Chemical compound C1=CC(F)=CC=C1C(C=1C=CC(F)=CC=1)CCCN1CCC(N2C(NC3=CC=CC=C32)=O)CC1 YVUQSNJEYSNKRX-UHFFFAOYSA-N 0.000 description 1
• 229960003634 pimozide Drugs 0.000 description 1
• 210000004910 pleural fluid Anatomy 0.000 description 1
• 229920000058 polyacrylate Polymers 0.000 description 1
• 229940113116 polyethylene glycol 1000 Drugs 0.000 description 1
• 229920000642 polymer Polymers 0.000 description 1
• 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
• 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
• 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
• 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 1
• 229940113124 polysorbate 60 Drugs 0.000 description 1
• 229920000053 polysorbate 80 Polymers 0.000 description 1
• 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
• 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
• 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
• 230000005195 poor health Effects 0.000 description 1
• 239000004302 potassium sorbate Substances 0.000 description 1
• 235000010241 potassium sorbate Nutrition 0.000 description 1
• 229940069338 potassium sorbate Drugs 0.000 description 1
• 235000012015 potatoes Nutrition 0.000 description 1
• 210000004909 pre-ejaculatory fluid Anatomy 0.000 description 1
• 239000002244 precipitate Substances 0.000 description 1
• 239000003755 preservative agent Substances 0.000 description 1
• 230000002265 prevention Effects 0.000 description 1
• FYPMFJGVHOHGLL-UHFFFAOYSA-N probucol Chemical compound C=1C(C(C)(C)C)=C(O)C(C(C)(C)C)=CC=1SC(C)(C)SC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 FYPMFJGVHOHGLL-UHFFFAOYSA-N 0.000 description 1
• 229960003912 probucol Drugs 0.000 description 1
• REQCZEXYDRLIBE-UHFFFAOYSA-N procainamide Chemical compound CCN(CC)CCNC(=O)C1=CC=C(N)C=C1 REQCZEXYDRLIBE-UHFFFAOYSA-N 0.000 description 1
• 229960000244 procainamide Drugs 0.000 description 1
• 238000004393 prognosis Methods 0.000 description 1
• 208000037821 progressive disease Diseases 0.000 description 1
• 230000002062 proliferating effect Effects 0.000 description 1
• 230000002035 prolonged effect Effects 0.000 description 1
• BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
• 229950008679 protamine sulfate Drugs 0.000 description 1
• 230000001681 protective effect Effects 0.000 description 1
• 238000000746 purification Methods 0.000 description 1
• 210000004915 pus Anatomy 0.000 description 1
• 238000003908 quality control method Methods 0.000 description 1
• 229960001404 quinidine Drugs 0.000 description 1
• 238000001959 radiotherapy Methods 0.000 description 1
• 206010037844 rash Diseases 0.000 description 1
• 230000009257 reactivity Effects 0.000 description 1
• 238000001953 recrystallisation Methods 0.000 description 1
• 229940100618 rectal suppository Drugs 0.000 description 1
• 239000006215 rectal suppository Substances 0.000 description 1
• 210000000664 rectum Anatomy 0.000 description 1
• 208000012802 recumbency Diseases 0.000 description 1
• 230000000306 recurrent effect Effects 0.000 description 1
• 235000020095 red wine Nutrition 0.000 description 1
• 201000000441 refractory hematologic cancer Diseases 0.000 description 1
• 230000001105 regulatory effect Effects 0.000 description 1
• 230000000717 retained effect Effects 0.000 description 1
• 201000006845 reticulosarcoma Diseases 0.000 description 1
• 208000029922 reticulum cell sarcoma Diseases 0.000 description 1
• JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 description 1
• 229960001225 rifampicin Drugs 0.000 description 1
• BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 description 1
• 229960000672 rosuvastatin Drugs 0.000 description 1
• 210000003296 saliva Anatomy 0.000 description 1
• 229920006395 saturated elastomer Polymers 0.000 description 1
• 239000012047 saturated solution Substances 0.000 description 1
• 210000002374 sebum Anatomy 0.000 description 1
• 210000000582 semen Anatomy 0.000 description 1
• 230000035945 sensitivity Effects 0.000 description 1
• 238000012163 sequencing technique Methods 0.000 description 1
• DFEYYRMXOJXZRJ-UHFFFAOYSA-N sevoflurane Chemical compound FCOC(C(F)(F)F)C(F)(F)F DFEYYRMXOJXZRJ-UHFFFAOYSA-N 0.000 description 1
• 229960002078 sevoflurane Drugs 0.000 description 1
• 230000001568 sexual effect Effects 0.000 description 1
• 238000010583 slow cooling Methods 0.000 description 1
• 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
• 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
• 230000003381 solubilizing effect Effects 0.000 description 1
• 239000004334 sorbic acid Substances 0.000 description 1
• 235000010199 sorbic acid Nutrition 0.000 description 1
• 229940075582 sorbic acid Drugs 0.000 description 1
• 239000001587 sorbitan monostearate Substances 0.000 description 1
• 235000011076 sorbitan monostearate Nutrition 0.000 description 1
• 229940035048 sorbitan monostearate Drugs 0.000 description 1
• ZBMZVLHSJCTVON-UHFFFAOYSA-N sotalol Chemical compound CC(C)NCC(O)C1=CC=C(NS(C)(=O)=O)C=C1 ZBMZVLHSJCTVON-UHFFFAOYSA-N 0.000 description 1
• 229960002370 sotalol Drugs 0.000 description 1
• DZZWHBIBMUVIIW-DTORHVGOSA-N sparfloxacin Chemical compound C1[C@@H](C)N[C@@H](C)CN1C1=C(F)C(N)=C2C(=O)C(C(O)=O)=CN(C3CC3)C2=C1F DZZWHBIBMUVIIW-DTORHVGOSA-N 0.000 description 1
• 229960004954 sparfloxacin Drugs 0.000 description 1
• 241000894007 species Species 0.000 description 1
• 238000001228 spectrum Methods 0.000 description 1
• 239000007921 spray Substances 0.000 description 1
• 238000011255 standard chemotherapy Methods 0.000 description 1
• 238000011301 standard therapy Methods 0.000 description 1
• 238000007920 subcutaneous administration Methods 0.000 description 1
• 208000011117 substance-related disease Diseases 0.000 description 1
• 235000011149 sulphuric acid Nutrition 0.000 description 1
• 230000036561 sun exposure Effects 0.000 description 1
• 230000000475 sunscreen effect Effects 0.000 description 1
• 239000000516 sunscreening agent Substances 0.000 description 1
• 239000000829 suppository Substances 0.000 description 1
• 238000004441 surface measurement Methods 0.000 description 1
• 238000011477 surgical intervention Methods 0.000 description 1
• 210000004243 sweat Anatomy 0.000 description 1
• 238000010408 sweeping Methods 0.000 description 1
• 239000007916 tablet composition Substances 0.000 description 1
• RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
• 210000001138 tear Anatomy 0.000 description 1
• 229960000351 terfenadine Drugs 0.000 description 1
• MHXBHWLGRWOABW-UHFFFAOYSA-N tetradecyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCC MHXBHWLGRWOABW-UHFFFAOYSA-N 0.000 description 1
• YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
• CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
• WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
• 229960000278 theophylline Drugs 0.000 description 1
• 230000036962 time dependent Effects 0.000 description 1
• 210000001519 tissue Anatomy 0.000 description 1
• XFYDIVBRZNQMJC-UHFFFAOYSA-N tizanidine Chemical compound ClC=1C=CC2=NSN=C2C=1NC1=NCCN1 XFYDIVBRZNQMJC-UHFFFAOYSA-N 0.000 description 1
• 229960000488 tizanidine Drugs 0.000 description 1
• UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 1
• 229960000303 topotecan Drugs 0.000 description 1
• 231100000331 toxic Toxicity 0.000 description 1
• 230000002588 toxic effect Effects 0.000 description 1
• 230000001052 transient effect Effects 0.000 description 1
• 238000011269 treatment regimen Methods 0.000 description 1
• 150000004684 trihydrates Chemical class 0.000 description 1
• 229910052722 tritium Inorganic materials 0.000 description 1
• 230000004614 tumor growth Effects 0.000 description 1
• 230000007306 turnover Effects 0.000 description 1
• 230000036325 urinary excretion Effects 0.000 description 1
• 229960000241 vandetanib Drugs 0.000 description 1
• 239000011782 vitamin Substances 0.000 description 1
• 235000013343 vitamin Nutrition 0.000 description 1
• 229940088594 vitamin Drugs 0.000 description 1
• 229930003231 vitamin Natural products 0.000 description 1
• 210000004916 vomit Anatomy 0.000 description 1
• 230000008673 vomiting Effects 0.000 description 1
• 229960005080 warfarin Drugs 0.000 description 1
• PJVWKTKQMONHTI-UHFFFAOYSA-N warfarin Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 description 1
• 239000001993 wax Substances 0.000 description 1
• 238000001262 western blot Methods 0.000 description 1
• 239000000080 wetting agent Substances 0.000 description 1
• 235000012794 white bread Nutrition 0.000 description 1
• 235000008939 whole milk Nutrition 0.000 description 1
• 210000002268 wool Anatomy 0.000 description 1
• 238000012447 xenograft mouse model Methods 0.000 description 1
• 150000003751 zinc Chemical class 0.000 description 1
• GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1